PT-141 MC4R Research: Melanocortin Receptor Pharmacology in Neuronal Cell Models
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with selective nanomolar affinity at MC3R and MC4R subtypes. In vitro neuronal cell model research characterises its receptor binding profile, Gs-cAMP signalling cascade activation, multi-pathway neuronal pharmacology, and receptor regulation dynamics in hypothalamic and neuronal cell line preparations.
MC4R Binding Affinity and Selectivity
Competitive radioligand displacement assays using [125I]-NDP-alpha-MSH in recombinant human MC1R, MC3R, MC4R, and MC5R HEK293 membrane preparations establish PT-141's Ki values and receptor subtype selectivity profile. PT-141 demonstrates nanomolar affinity at MC3R and MC4R with substantially lower potency at MC1R and MC5R, classifying it as a mixed MC3R/MC4R agonist. Selectivity ratios — MC4R Ki versus MC1R Ki — are determined in parallel binding assays to quantify the receptor selectivity margin relevant to neuronal cell model research applications.
Gs-cAMP Signalling in MC4R Cell Models
MC4R is a constitutively active Gs-coupled GPCR with approximately 20–30% basal activity in the absence of agonist. PT-141 binding increases adenylate cyclase activity above constitutive baseline, producing concentration-dependent cAMP accumulation quantified by HTRF assay in HEK293-hMC4R stable cell lines. EC50 values and intrinsic efficacy relative to alpha-MSH and NDP-alpha-MSH reference agonists are established in matched assay conditions. Constitutive activity controls using inverse agonist AgRP(83-132) contextualise PT-141 agonism against the full MC4R activity range.
Neuronal Cell Model Applications
GT1-7 hypothalamic neuronal cell lines and SH-SY5Y neuroblastoma preparations expressing endogenous or transfected MC4R serve as primary neuronal model systems for PT-141 pharmacology. Multi-endpoint signalling assays in these neuronal models characterise Gs-cAMP pathway activation, ERK1/2 Thr202/Tyr204 phosphorylation kinetics by immunoblot, intracellular calcium mobilisation by Fura-2 AM imaging, and neuropeptide gene expression changes (NPY, AgRP, POMC, CART) by quantitative PCR following PT-141 treatment at defined concentrations.
Beta-Arrestin Recruitment and Receptor Trafficking
BRET-based beta-arrestin 2 recruitment assays in HEK293-hMC4R preparations quantify PT-141's capacity to engage the arrestin-mediated internalisation pathway relative to alpha-MSH and biased MC4R agonist reference compounds. Transduction ratio analysis distinguishes Gs-biased from balanced agonism. GFP-tagged MC4R construct trafficking studies by confocal microscopy track receptor internalisation at 15, 30, and 60 minutes post-PT-141 treatment, with Rab5 and Rab11 co-localisation studies characterising early endosomal routing and recycling pathway engagement in neuronal cell model preparations.
Comparative Pharmacology with Melanocortin Reference Compounds
Side-by-side comparison of PT-141, alpha-MSH, NDP-alpha-MSH, and Melanotan II in MC4R binding, cAMP, calcium, and beta-arrestin recruitment assays establishes relative potency and efficacy relationships in matched assay conditions. Schild regression analysis using selective MC4R antagonist HS024 confirms competitive antagonism and on-target receptor mediation of PT-141 signalling. These comparative data position PT-141 within the melanocortin agonist pharmacology landscape for neuronal cell model research.
Hypothalamic Neuropeptide Pathway Context
GT1-7 and mHypoE-N46 hypothalamic cell model preparations contextualise PT-141 MC4R pharmacology within the melanocortin-neuropeptide signalling network. POMC processing enzyme (PC1/3, PC2) expression, melanocortin receptor expression profiling by flow cytometry, and AMPK phosphorylation status alongside canonical cAMP signalling characterise the broader neuronal signalling landscape modulated by MC4R activation. These multi-pathway data provide comprehensive neuronal pharmacology context for PT-141 receptor characterisation in vitro.
Research Summary
PT-141 demonstrates defined nanomolar MC3R/MC4R binding affinity, Gs-cAMP pathway activation, multi-pathway neuronal signalling including ERK1/2 and calcium components, and characterised receptor trafficking dynamics in neuronal cell model preparations. Its comprehensive melanocortin receptor pharmacology profile and neuronal model compatibility support its utility as a reference compound for in vitro MC4R signalling research.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
